Clinical trials: NPC
Nasopharyngeal Cancinoma (NPC)
Sodium Bicarbonate for Reducing Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma.
To evaluate whether the use of 2.5% sodium bicarbonate mouthwash throughout the entire course of radiotherapy for nasopharyngeal carcinoma reduces the severity of radiation-induced oral mucositis and improves patient adherence to…
- Trial name
- NCT06854510
- Testing
- Gargle with 2.5% sodium bicarbonate solution during radiotherapy, Gargle with 0.9% sodium chloride solution during radiotherapy
- Where
- China
- Volunteers
- 196 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Cancinoma (NPC)
Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal Carcinoma
Re-irradiation is the most common clinical treatment for recurrent nasopharyngeal carcinoma; however, it is associated with severe complications which seriously affect patients' quality of life.
- Trial name
- NCT07528183
- Testing
- Maintenance Immunotherapy With Deferred Salvage Radiotherapy
- Where
- 4 sites in China
- Volunteers
- 62 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma (NPC)
Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma
This trial aims to study the role of Ivonescimab combined with chemoradiotherapy in high-Risk locoregionally advanced nasopharyngeal carcinoma.
- Trial name
- NCT07064902
- Testing
- Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）
- Where
- 3 sites in China
- Volunteers
- 48 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma (NPC)
Efficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab "Immune Sandwich" Regimen Versus Full-Course Immunotherapy for Locally Advanced Nasopharyngeal Carcinoma
Immunotherapy combined with chemoradiotherapy has become standard care for locally advanced nasopharyngeal carcinoma, yet radiotherapy-induced lymphopenia may impair the efficacy of concurrent PD-1 blockade.
- Trial name
- NCT07706985
- Testing
- Toripalimab combined with Nimotuzumab, Nimotuzumab
- Where
- China
- Volunteers
- 566 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Cancinoma (NPC)
Efficacy and Safety of Becotatug Vedotin (MRG003) Combined With Anti-PD1 as Maintenance Therapy for Recurrent and Metastatic Nasopharyngeal Carcinoma
This multicenter randomized controlled Phase III trial assesses the efficacy and safety of becotatug vedotin plus anti-PD-1 antibody as maintenance therapy for recurrent/metastatic nasopharyngeal carcinoma.
- Trial name
- NCT07705243
- Testing
- Anti-PD1, Anti-PD1 combined with Becotatug Vedotin
- Where
- China
- Volunteers
- 86 people
- Sponsor
- Sun Yat-sen University
Recurrent/ Metastatic NPC
JS207 a Bispecific Antibody Against PD1-VEGF in Nasopharyngeal Carcinoma
This study is to determine the activity and tolerability of JS207 as a single agent and in combination cohort with chemotherapy.
- Trial name
- NCT07690787
- Testing
- JS207, Paclitaxel, Capecitabine
- Where
- Hong Kong
- Volunteers
- 49 people
- Sponsor
- Chinese University of Hong Kong
Nasopharyngeal Cancinoma (NPC)
Multimodal Evaluation-Guided Surveillance-Intervention With Endoscopic Selective Neck Dissection for Post-Radiotherapy N3 Nasopharyngeal Carcinoma
This randomized trial evaluates a multimodal surveillance strategy in nasopharyngeal carcinoma patients with high-risk N3 cervical lymph node involvement after radiotherapy.
- Trial name
- NCT07692906
- Testing
- Multimodal Evaluation-Guided Surveillance Strategy
- Volunteers
- 80 people
- Sponsor
- Xuelei Ma MD
Nasopharyngeal Carcinoma (NPC)
A Multicenter, Prospective, Phase III Clinical Study of Proton Intensity-modulated Radiotherapy Versus Photon Intensity-modulated Radiotherapy for Untreated Non-metastatic Nasopharyngeal Carcinoma
Proton therapy for nasopharyngeal carcinoma can reduce radiotherapy-related toxic reactions, and some retrospective studies have found that proton therapy improves the survival of patients with nasopharyngeal carcinoma.
- Trial name
- NCT07578727
- Testing
- Proton Therapy System (ProBeam), Photon Therapy System (TrueBeam)
- Where
- 2 sites in China
- Volunteers
- 504 people
- Sponsor
- Guangzhou Concord Cancer Center
Nasopharyngeal Cancinoma (NPC)
LDRT and Chemoimmunotherapy in NPC With Liver Metastasis
This study aims to evaluate the efficacy and toxicity of adding low-dose radiotherapy to chemoimmunotherapy as a first-line treatment for nasopharyngeal carcinoma patients with liver metastasis.
- Trial name
- Light (NCT06788002)
- Testing
- Low-dose radiotherapy combine with chemoimmunotherapy
- Where
- 8 sites in China
- Volunteers
- 26 people
- Sponsor
- Hunan Cancer Hospital
Xerostomia, Head Cancer
Evaluating the Optimal Timing of Acupuncture for Managing Chemoradiation-induced Xerostomia in Patients With Head and Neck Cancers
While existing data supports the use of acupuncture to reduce radiation-induced xerostomia, the optimal timing of acupuncture for managing chemoradiation-induced xerostomia remains an area of active investigation.
- Conditions
- Xerostomia, Head Cancer, Neck Cancer, Nasopharyngeal Carcinoma (NPC)
- Trial name
- NCT07674706
- Testing
- Acupuncture
- Where
- Singapore
- Volunteers
- 50 people
- Sponsor
- National University Hospital, Singapore
Nasopharyngeal Carcinoma (NPC), Locoregionally Advanced Nasopharyngeal Carcinoma
Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma
This is a phase 2, multicentre, open-label, randomised, controlled trial with a parallel-group design. The study aims to evaluate the efficacy and safety of single-agent Becotatug Vedotin as adjuvant therapy in patients with…
- Conditions
- Nasopharyngeal Carcinoma (NPC), Locoregionally Advanced Nasopharyngeal Carcinoma, Adjuvant Therapy
- Trial name
- NCT07303283
- Testing
- Becotatug Vedotin
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Kai Hu
Nasopharyngeal Carcinoma (NPC)
RAIRI Model-Guided Adjuvant Therapy in Nasopharyngeal Carcinoma
This study aims to evaluate a personalized approach for treating patients with locoregionally advanced nasopharyngeal carcinoma (NPC).
- Trial name
- RAIRI-NPC (NCT07590024)
- Testing
- PD-1 inhibitor, Capecitabine
- Where
- China
- Volunteers
- 651 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Nasopharyngeal Carcinoma (NPC)
Real-World RAIRI-Guided Risk Stratification for Adjuvant Therapy Benefit After Chemoradiotherapy in NPC
This prospective, multicenter, real-world observational study aims to evaluate whether a response-adapted individualized risk index, the RAIRI model, can identify patients with non-metastatic nasopharyngeal carcinoma who may or…
- Trial name
- NCT07618078
- Testing
- PD-1 inhibitor, Capecitabine
- Where
- China
- Volunteers
- 900 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Advanced or Metastatic Squamous Non-Small Cell Lung Cancer, Advanced Head and Neck Squamous Cell Carcinoma
A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
This is a Phase Ib/II multi-center, open-label study of HMBD-001 in combination with cetuximab with or without docetaxel in participants with advanced Squamous Cell Cancers
- Conditions
- Advanced or Metastatic Squamous Non-Small Cell Lung Cancer, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Esophageal Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma
- Trial name
- NCT05910827
- Testing
- HMBD-001, Docetaxel, Cetuximab
- Where
- 20 sites in Australia, Moldova and 3 more
- Volunteers
- 398 people
- Sponsor
- Hummingbird Bioscience
Nasopharyngeal Cancinoma (NPC), Nasopharangeal Cancer
LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC
This study aims to evaluate the efficacy and safety of LDRT combined with toripalimab and GP chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma through a prospective, open-label, single-arm Phase II…
- Trial name
- LIGHT (NCT07325539)
- Testing
- Gemcitabine(GEM), Cisplatin, Toripalimab
- Where
- 2 sites in China
- Volunteers
- 55 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Cancinoma (NPC), Recurrent Nasopharynx Carcinoma
EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma
This is a prospective, single-arm, phase II clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of EGFR antibody combined with programmed death 1 (PD-1) antibody and chemotherapy in…
- Conditions
- Nasopharyngeal Cancinoma (NPC), Recurrent Nasopharynx Carcinoma, Metastatic Nasopharyngeal Carcinoma
- Trial name
- NCT06802835
- Testing
- EGFR Antibody, PD-1 antibody, Gemcitabine, Cisplatin
- Where
- China
- Volunteers
- 148 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Cancinoma (NPC), Radiation-induced Oral Mucositis
Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid
To explore the efficacy of Houyanqing Oral Liquid combined with conventional treatment in preventing and treating radiation-induced oral mucositis, so as to improve the quality of life of nasopharyngeal carcinoma patients…
- Trial name
- NCT07311772
- Testing
- Houyanqing Oral Liquid, Conventional Treatment for Radiation-Induced Oral Mucositis
- Where
- 16 sites in China
- Volunteers
- 386 people
- Sponsor
- Sun Yat-sen University
Oral Mucositis (Ulcerative) Due to Radiation, Nasopharyngeal Carcinoma (NPC)
Taurine for the Prevention and Treatment of Radiation-induced Oral Mucositis in Patients With Nasopharyngeal Carcinoma
This clinical trial aims to understand whether taurine can prevent and reduce severe radiation-induced oral mucositis in patients with nasopharyngeal carcinoma undergoing radiotherapy.
- Trial name
- NCT07567742
- Testing
- Taurine
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Cancinoma (NPC)
International Collaborative Study on AJCC/UICC TNM-10 for Nasopharyngeal Cancer
The goal of this international, multicenter, prospective observational study is to improve prognostication and prediction of failure pattern for nasopharyngeal carcinoma (NPC), in order to provide more accurate guidance for…
- Trial name
- NCT07013461
- Where
- China
- Volunteers
- 5,000 people
- Sponsor
- The University of Hong Kong-Shenzhen Hospital
Nasopharyngeal Carcinoma (NPC)
Evaluating Ivonescimab in PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma
This study is designed as a single-arm, open-label, phase II trial to evaluate the efficacy and safety of ivonescimab in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) who have progressed on prior an immune…
- Trial name
- AK112 (NCT07565389)
- Testing
- Ivonescimab 20 mg/kg
- Where
- Singapore
- Volunteers
- 42 people
- Sponsor
- National University Hospital, Singapore